Patents by Inventor Jonathan P. Belk
Jonathan P. Belk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11485795Abstract: The present invention provides an antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), an antigen-binding fragment of the antibody, and a composition comprising the antibody or the fragment. Also provided are a nucleic acid that encodes the antibody or the fragment, a host cell containing the nucleic acid, and applications of the antibody and fragment in treatment and diagnosis.Type: GrantFiled: December 22, 2017Date of Patent: November 1, 2022Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTDInventors: Andy Tsun, Eric Krauland, Jonathan P Belk, Xiaoniu Miao, Min Zhang, Nadthakarn Boland, Xiaolin Liu, Dechao Yu
-
Patent number: 11344621Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: August 27, 2018Date of Patent: May 31, 2022Assignee: Abbvie, Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
-
Publication number: 20200087416Abstract: The present invention provides an antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), an antigen-binding fragment of the antibody, and a composition comprising the antibody or the fragment. Also provided are a nucleic acid that encodes the antibody or the fragment, a host cell containing the nucleic acid, and applications of the antibody and fragment in treatment and diagnosis.Type: ApplicationFiled: December 22, 2017Publication date: March 19, 2020Inventors: Andy TSUN, Eric KRAULAND, Jonathan P BELK, Xiaoniu MIAO, Min ZHANG, Nadthakarn BOLAND, Xiaolin LIU, Dechao YU
-
Publication number: 20190008966Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: August 27, 2018Publication date: January 10, 2019Applicant: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
-
Patent number: 10086076Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: March 13, 2017Date of Patent: October 2, 2018Assignee: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
-
Publication number: 20170340737Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: March 13, 2017Publication date: November 30, 2017Inventors: Chengbin WU, Richard W. DIXON, Jonathan P. BELK, Hua YING, Maria A. ARGIRIADI, Carolyn A. CUFF, Paul R. HINTON, Shankar KUMAR, Terry L. MELIM, Yan CHEN
-
Patent number: 9592293Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: December 9, 2013Date of Patent: March 14, 2017Assignee: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Publication number: 20160153001Abstract: This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.Type: ApplicationFiled: October 28, 2015Publication date: June 2, 2016Inventors: Chung-ming Hsieh, Jonathan P. Belk, Jennifer M. Perez, Lorenzo Benatuil
-
Patent number: 9200270Abstract: This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.Type: GrantFiled: March 3, 2009Date of Patent: December 1, 2015Assignee: AbbVie Inc.Inventors: Chung-ming Hsieh, Jonathan P. Belk, Jennifer M. Perez, Lorenzo Benatuil
-
Publication number: 20140178332Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.Type: ApplicationFiled: January 13, 2014Publication date: June 26, 2014Applicant: ABBVIE INC.Inventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
-
Publication number: 20140099313Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: ABBVIE INC.Inventors: Chengbin WU, Richard W. DIXON, Jonathan P. BELK, Maria A. ARGIRIADI, Hua YING, Carolyn A. CUFF, Terry L. MELIM, Shankar KUMAR, Paul R. HINTON, Yan CHEN
-
Patent number: 8629257Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.Type: GrantFiled: April 19, 2010Date of Patent: January 14, 2014Assignee: Abbvie Inc.Inventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
-
Patent number: 8604177Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: March 8, 2011Date of Patent: December 10, 2013Assignee: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Publication number: 20110165066Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: March 8, 2011Publication date: July 7, 2011Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Patent number: 7915388Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: September 7, 2007Date of Patent: March 29, 2011Assignee: Abbott LaboratoriesInventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Publication number: 20100196315Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.Type: ApplicationFiled: April 19, 2010Publication date: August 5, 2010Applicant: ABBOTT LABORATORIESInventors: Susan E. LACY, Emma FUNG, Jonathan P. BELK, Richard W. DIXON, Michael ROGUSKA, Paul R. HINTON, Shankar KUMAR
-
Patent number: 7700739Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.Type: GrantFiled: June 29, 2006Date of Patent: April 20, 2010Assignee: Abbott LaboratoriesInventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
-
Publication number: 20100047245Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.Type: ApplicationFiled: June 29, 2006Publication date: February 25, 2010Inventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
-
Publication number: 20090264320Abstract: This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.Type: ApplicationFiled: March 3, 2009Publication date: October 22, 2009Inventors: Chung-ming Hsieh, Jonathan P. Belk, Jennifer M. Perez, Lorenzo Benatuil
-
Publication number: 20080171014Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: September 7, 2007Publication date: July 17, 2008Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen